Go Back
mRNA-LNP Encapsulation
Building on our mRNA technology platform, we now offer mRNA-LNP technology services in addition to our research-grade mRNA production services. Our platform utilizes mainstream microfluidic technology, which is simple, fast, and operates under mild conditions, making it suitable for scale-up production. We have optimized key process parameters to enhance the consistency and reproducibility of mRNA drug production. Currently, our LNP formulation platform is compatible with various formulations and achieves encapsulation efficiencies of over 90%.
More Details
Description
Building on our mRNA technology platform, we now offer mRNA-LNP technology services in addition to our research-grade mRNA production services. Our platform utilizes mainstream microfluidic technology, which is simple, fast, and operates under mild conditions, making it suitable for scale-up production. We have optimized key process parameters to enhance the consistency and reproducibility of mRNA drug production. Currently, our LNP formulation platform is compatible with various formulations and achieves encapsulation efficiencies of over 90%.
Procedure
- Buffer Preparation: Preparation of two liquid streams: one containing aqueous buffer and the other with lipids dissolved in ethanol for mRNA.
- Microfluidics: Microfluidic devices are used to rapidly mix lipid and mRNA solutions, resulting in uniform LNPs and high encapsulation efficiency.
- Tangential Flow Filtration: Ultrafiltration technology is employed to concentrate the solution to the target formulation concentration, replace the buffer with a neutral storage solution, and remove unencapsulated mRNA, excess lipids, and ethanol.
Service Details
Note: The actual preparation time may vary depending on the sample.
Deliverables
- mRNA-LNP Formulation
- COA
Service Advantages
- Formulation Optimization: Fast synthesis speeds up research and development efficiency, allowing for pre-optimization of formulation plans.
- High Encapsulation Efficiency: By optimizing the content of LNP components and the ratio of aqueous to organic phases, mRNA-LNP encapsulation efficiency can be increased to over 90%.
- Excellent Nanoparticle Characterization: Stable platform process controls LNP particle size at 80-100 nm, ensuring uniform size distribution (PDI < 0.10).
- Efficient Expression: Pre-formulated mRNA-LNPs are validated for high-efficiency expression of target proteins in in vitro cell assays.
Only for research and not intended for treatment of humans or animals
